30 June 2022
Apollon Formularies Plc
("Apollon" or the "Company")
Total Voting Rights
In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that it has 752,725,356 ordinary shares of no par value each in issue, each share carrying the right to one vote.
This figure of 752,725,356 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information please contact:
Apollon Formularies
Tel: +44 771 198 0221
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
BlytheRay (Financial PR/IR-
Tel: +44 207 138 3204
Tim Blythe/Megan Ray apollon@blytheray.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis company headquartered in the